Herpes zoster: current approaches to diagnosis and treatment
DOI: https://doi.org/10.29296/25877305-2022-10-04
Issue:
10
Year:
2022
The paper considers the clinical characteristics of herpes zoster (HZ) and its complications in different patient categories. It gives the pharmacokinetics and pharmacodynamics of unusual nucleoside agents in the treatment of varicella-zoster virus infection. The authors show the advantages of famciclovir in the therapy of HZ, particularly the effect of the drug on the manifestations of acute herpetic neuralgia and its ability to reduce the risk of post-herpetic neuralgia.
Keywords:
dermatology
neurology
herpes zoster
post-herpetic neuralgia
famciclovir
References:
- Heininger U., Seward J.F. Varicella. Lancet. 2006; 368: 1365e76. DOI: 10.1016/S0140-6736(06)69561-5
- Афонина Н., Михеева И. Современная эпидемиологическая характеристика ветряной оспы в России. One Health & Risk Management. 2020; 1 (1): 12–21 [Afonina N., Mikheeva I. Modern epidemiological characteristics of chickenpox in Russia. One Health & Risk Management. 2020; 1 (1): 12–21 (in Russ.)]. DOI: 10.5281/zenodo.3700955
- John A.R., Canaday D.H. Herpes zoster in the older adult. Infect Dis Clin North Am. 2017; 31 (4): 811–26. DOI: 10.1016/j.idc.2017.07.016
- Опоясывающий герпес. Федеральные клинические рекомендации. Дерматовенерология [интернет]. М., 2016; с. 305–14 [Federal clinical guidelines. Dermatovenereology [Internet]. M., 2016; рр. 305–14 (in Russ.)]. URL: http://www.cnikvi.ru/docs/2335_maket_30.pdf
- Колоколов О.В., Бакулев А.Л., Шульдяков А.А. и др. Поражение нервной системы, ассоциированное с герпесвирусом человека третьего типа: акценты на профилактику боли и инсульта. Клиническая практика. 2019; 10 (2): 74–84 [Kolokolov O.V., Bakulev A.L., Shuldyakov A.A. et al. Nervous system damage associated with human herpesvirus of the third type: emphasis on the prevention of pain and stroke. Clinical practice. 2019; 10 (2): 74–84 (in Russ.)]. DOI: 10.17816/clinpract10274–84
- Цукер М.Б. Поражения нервной системы, вызываемые вирусами группы герпеса. Клиническая медицина. 1976; 54 (9): 90–7 [Zucker MB. Defeats of the nervous system caused by viruses of the herpes group. Klinicheskaia meditsina. 1976; 54 (9): 90–7 (in Russ.)].
- Wang Z., Ye J., Han Y.H. Acute pancreatitis associated with herpes zoster: case report and literature review. World J Gastroenterol. 2014; 20 (47): 18053–6. DOI: 10.3748/wjg.v20.i47.18053
- Таха Т.В. Опоясывающий герпес: клиника, диагностика, принципы терапии. РМЖ. 2012; 20 (34): 1644–8 [Taha T.V. Herpes zoster: clinic, diagnosis, principles of therapy. RMJ. 2012; 20 (34): 1644–8 (in Russ.)].
- Dworkin R., Gnann G., Oaklander A. et al. Diagnosis and assessment of pain associated with herpes zoster and postgerpetic neuralgia. J Pain. 2008; 9(1 Suppl 1): S37–44. DOI: 10.1016/j.jpain.2007.10.008
- Деконенко Е.П. Клинические проявления, частота и лечение заболеваний, вызываемых вирусом варицелла-зостер. Альманах клинической медицины. 2001; 4: 271–5 [Dekonenko E.P. Clinical manifestations, frequency and treatment of diseases caused by varicella-zoster virus. Almanah of clinical medicine. 2001; 4: 271–5 (in Russ.)].
- Saru S., Gupta R., Kaur S. et al. Post-herpetic neuralgia: review of current management strategies. Indian J Pain. 2013; 27 (1): 12–21. DOI: 10.4103/0970-5333.114857
- Schmader K.E. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain. 2002; 18 (6): 350–4. DOI: 10.1097/00002508-200211000-00002
- Dworkin R.H. et al. Acute pain in herpes zoster: the famciclovir database project. Pain. 2001; 94 (1): 113–9. DOI: 10.1016/S0304-3959(01)00347-5
- Whitley R.J. Varicella-zuster virus infections. In: Galasso G.J., Whitley R.J., Merigan T.C., eds. Antiviral agents and virus diseases of man, 3rd edn. 1990; рр. 235–63.
- Kost R.G., Straus S.E. Postherpetic neuralgia-pathogenesis, treatment, and prevention [review]. N Engl J Med. 1996; 335 (1): 32–42. DOI: 10.1056/NEJM199607043350107
- Волкова Л.В. Современные аспекты лечения и профилактики постгерпетической невралгии. Вестник фармации. 2009; 6: 34–7. [Volkova L.V. Modern aspects of treatment and prevention of postherpetic neuralgia. Bulletin of Pharmacy. 2009; 6: 34–7 (in Russ.)].
- Sampathkumar P., Drage L.A., Martin D.P. Herpes zoster (shingles) and postherpetic neuralgia. Mayo Clin Proc. 2009; 84 (3): 274–80. DOI: 10.4065/84.3.274
- Truini A., Galeotti F., Haanpaa M. et al. Pathophysiology of pain in postherpetic neuralgia:a clinical and neurophysiological study. Pain. 2008; 140 (3): 405–10. DOI: 10.1016/j.pain.2008.08.018
- Opstelten W., McElhaney J., Weinberger B. et al.The impact of varicella zoster virus: chronic pain. J Clin Virol. 2010; 48 (Suppl 1): S8–13. DOI: 10.1016/S1386-6532(10)70003-2
- Ruocco V., Sangiuliano S., Brunetti G. et al. Beyond zoster: sensory and immune changes in zoster-affected dermatomes: a review. Acta Derm Venereol. 2012; 92 (4): 378–82. DOI: 10.2340/00015555-1284
- Grahn A., Studahl M. Varicella-zoster virus infections of the central nervous system – prognosis, diagnostics and treatment. J Infect. 2015; 71 (3): 281–93. DOI: 10.1016/j.jinf.2015.06.004
- Wu P.H., Chuang Y.S., Lin Y.T. Does Herpes Zoster increase the risk of stroke and myocardial infarction? A comprehensive review. J Clin Med. 2019; 8 (4): pii: E547. DOI: 10.3390/jcm8040547
- Johnson R.W., Dworkin R.H. Treatment of herpes zoster and postherpetic neuralgia. BMJ. 2003; 326 (7392): 748–50. DOI: 10.1136/bmj.326.7392.748
- Sauerbrei A. Diagnosis, antiviral therapy, and prophylaxis of varicella-zoster virus infections. Eur J Clin Microbiol Infect Dis. 2016; 35: 723e34. DOI: 10.1007/s10096-016-2605-0
- O’Brien J.J., Campoli-Richards D.M. Acyclovir. An updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs. 1989; 37 (3): 233–309. DOI: 10.2165/00003495-198937030-00002
- Wood M.J. et al. Efficacy of oral acyclovir treatment of acute herpes zoster. Am J Med. 1988; 85 (2A): 79–83.
- Huff J.C. et al. Therapy of herpes zoster with oral acyclovir // The Am J Med. 1988; 85 (2A): 84–9.
- Huff J.C. et al. Effect of oral acyclovir on pain resolution in herpes zoster: a reanalysis. J Med Virol. 1993; 41 (S1): 93–6. DOI: 10.1002/jmv.1890410518
- Chen N. et al. Antiviral treatment for preventing postherpetic neuralgia. Cochrane Database Syst Rev. 2014; 2: CD006866. DOI: 10.1002/14651858.CD006866.pub3
- Lilie H.M., Wassilew S.W. The role of antivirals in the management of neuropathic pain in the older patient with herpes zoster. Drugs Aging. 2003; 20 (8): 561–70. DOI: 10.2165/00002512-200320080-00002
- Шаков И.М. Опоясывающий лишай. Лечащий врач. 2011; 10: 14. [Shakov I.M. Shingles. Lechaschi Vrach. 2011; 10: 14 (in Russ.)].
- Beutner K.R. et al. Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother. 1995; 39 (7): 1546–53. DOI: 10.1128/AAC.39.7.1546
- Segarra-Newnham M., Tagoff S.S. Valacyclovir and postherpetic neuralgia. J Pharm Technol. 2004; 20 (4): 229–32.
- Opstelten W. et al. Treatment of herpes zoster. Can Fam Physician. 2008; 54 (3): 373–7.
- Crumpacker C. The pharmacological profile of famciclovir. Semin Dermatol. 1996; 15 (2 Suppl 1): 14–26.
- Tyring S.K. Advances in the treatment of herpesvirus infection: the role of famciclovir. Clin Ther. 1998; 20 (4): 661–70. DOI: 10.1016/s0149-2918(98)80129-x
- Pue M.A. et al. Linear pharmacokinetics of penciclovir following administration of single oral doses of famciclovir 125, 250, 500 and 750 mg to healthy volunteers. J Antimicrob Chemother. 1994; 33 (1): 119–27. DOI: 10.1093/jac/33.1.119
- Bacon T.H. et al. Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy. Clin Microbiol Rev. 2003; 16 (1): 114–28. DOI: 10.1128/CMR.16.1.114-128.2003
- Data on file. Philadelphia, Pa: Smith Kline Beecham, 1998.
- Dworkin R.H. et al. Postherpetic neuralgia: impact of famciclovir, age, rash severity, and acute pain in herpes zoster patients. J Infect Dis. 1998; 178 (Suppl 1): S76–S80. DOI: 10.1086/514260
- Earnshaw D.L. et al. Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus. Antimicrob Agents Chemother. 1992; 36 (12): 2747–57. DOI: 10.1128/AAC.36.12.2747
- Perry C.M., Wagstaff A.J. Famciclovir. A review of its pharmacological properties and therapeutic efficacy in herpesvirus infections. Drugs. 1995; 50 (2): 396–415. DOI: 10.2165/00003495-199550020-00011
- Pue M.A., Benet L.Z. Pharmacokinetics of famciclovir in man. Antiviral Chem Chemother. 1993; 4 (6 suppl): 47–55. DOI: 10.1177/09563202930040S602
- Cirelli R. et al. Famciclovir: review of clinical efficacy and safety. Antiviral Res. 1996; 29 (2-3): 141–51. DOI: 10.1016/0166-3542(95)00941-8
- Sacks S.L. Famciclovir (FAMVIR®). Infect Dis Obstet Gynecol. 1997; 5 (1): 3–7. DOI: 10.1155/S1064744997000033
- Boyd M.R., Safrin S., Kern E.R. Penciclovir: a review of spectrum of activity, selectivity, and cross-resistance pattern. Antiviral Chem Chemother. 1993; 4 (Suppl 1): 3–11. DOI: 10.1177/095632029300401S01
- Bacon T., Schinazi R. An overview of the further evaluation of penciclovir against herpes simplex virus and varicella-zoster virus in cell culture, highlighting contrasts with acyclovir. Antiviral Chem Chemother. 1993; 4 (Suppl 1): 25–36. DOI: 10.1177/09563202930040S603
- Standring-Cox R., Bacon T.H., Howard B. et al. Prolonged activity of penciclovir in cell culture against varicella-zoster virus [Abstract]. Antiviral Res. 1994; 23 (Suppl 1): 96.
- Tyring S. et al. Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1995; 123 (2): 89–96. DOI: 10.7326/0003-4819-123-2-199507150-00002
- Ono F. et al. Comparison between famciclovir and valacyclovir for acute pain in adult Japanese immunocompetent patients with herpes zoster. J Dermatol. 2012; 39 (11): 902–8. DOI: 10.1111/j.1346-8138.2012.01584.x
- Tyring S.K., Beutner K.R., Tucker B.A. et al. Antiviral therapy for herpes zoster: randomized, controlled clinical trial of valacyclovir and famciclovir therapy in immunocompetent patients 50 years and older. Arch Fam Med. 2000; 9: 863–9. DOI: 10.1001/archfami.9.9.863
- Bacon T.H. et al. Inhibition of varicella-zoster virus by penciclovir in cell culture and mechanism of action. Antiviral Chem Chemother. 1996; 7 (2): 71–8. DOI.: 10.1177/095632029600700203
- Johnson R.W. Herpes zoster – predicting and minimizing the impact of post-herpetic neuralgia. J Antimicrob Chemother. 2001; 47 (suppl 1): 1–8. DOI: 10.1093/jac/47.suppl_1.1
- Krieble B.F., Rudy D.W., Glick M.R. et al. Case report: acyclovir neurotoxicity and nephrotoxicity e the role for hemodialysis. Am J Med Sci. 1993; 305: 36e9. DOI: 10.1097/00000441-199301000-00007
- Becker B.N., Fall P., Hall C. et al. Rapidly progressive acute renal failure due to acyclovir: case report and review of the literature. Am J Kidney Dis. 1993; 22: 911e5. DOI: 10.1016/s0272-6386(12)80939-5
- Sodhi P.K., Ratan S.K. A case of chronic renal dysfunction following treatment with oral acyclovir. Scand J Infect Dis. 2003; 35 (10): 770–2. DOI: 10.1080/00365540310016574-1
- Yavuz B.B., Cankurtaran M., Halil M. et al. Renal dysfunction after oral acyclovir treatment in a geriatric woman: a case report. Scand J Infect Dis. 2005; 37 (8): 611–3.
- Htwe T.H., Bergman S., Koirala J. Famciclovir substitution for patients with acyclovir-associated renal toxicity. J Infect. 2008; 57 (3): 266–8. DOI: 10.1016/j.jinf.2008.06.008
- Linnemann C.C. Jr., Biron K.K., Hoppenjans W.G. et al. Emergence of acyclovir-resistant varicella zoster virus in an AIDS patient on prolonged acyclovir therapy. AIDS. 1990; 4: 577–9. DOI: 10.1097/00002030-199006000-00014
- Shimizu R., Ohwada C., Nagao Y. et al. The successful treatment of a cord blood transplant recipient with varicella zoster virus meningitis, radiculitis and myelitis with foscarnet. Intern Med. 2017; 56: 353–6. DOI: 10.2169/internalmedicine.56.6930
- Manzano V. et al. Severe pneumonia by aciclovir-resistant varicella-zoster virus during etanercept therapy. Rheumatology. 2010; 49 (9): 1791–3. DOI: 10.1093/rheumatology/keq110
- Tomomi Oka, Masakatsu Hishizawa, Kouhei Yamashita et al. Successful treatment with famciclovir for varicella zoster virus infection resistant to acyclovir. J Infect Chemother. 2021; 27 (5): 755–8. DOI: 10.1016/j.jiac.2020.12.013
- Werner R.N. et al. European consensus-based (S2k) Guideline on the Management of Herpes Zoster–guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV), Part 2: Treatment. J Eur Acad Dermatol Venereol. 2017; 31 (1): 20–9. DOI: 10.1111/jdv.13957
- Rivaud E. et al. Valacyclovir hydrochloride therapy and thrombotic thrombocytopenic purpura in a HIV-infected patient. Arch Intern Med. 2000; 160 (11): 1705–6. DOI: 10.1001/archinte.160.11.1705
- Bukhari S. et al. Valacyclovir-Induced Thrombotic Thrombocytopenic Purpura. Cureus. 2020; 12 (5): e8156. DOI: 10.7759/cureus.8156
- Becker S. et al. HIV-associated thrombotic microangiopathy in the era of highly active antiretroviral therapy: an observational study. Clin Infect Dis. 2004; 39 (Suppl 5): S267–S275. DOI: 10.1086/422363
- Oxman M.N., Levin M.J., Johnson G.R. et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005; 352 (22): 2271–84. DOI: 10.1056/NEJMoa051016